We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation
Read MoreHide Full Article
Bristol-Myers (BMY - Free Report) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for its experimental candidate, lisocabtagene maraleucel (liso-cel).
Liso-cel, an experimental CD19-directed chimeric antigen receptor (CAR) T cell therapy, is being evaluated for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B) after at least two prior therapies.
The validation of the application confirms that the submission is complete and the EMA will begin its centralized review process.
The application was based on results from TRANSCEND NHL 001, the largest study in third-line or greater R/R large B-cell lymphoma (LBCL), and additional data from the TRANSCEND WORLD study. The studies evaluated patients with R/R LBCL and included patients with a broad range of histologies and high-risk disease as well as those who received liso-cel in the outpatient setting.
We note that the EMA previously granted liso-cel access to the PRIME scheme for the treatment of R/R DLBCL and Accelerated Assessment status, which reduces the maximum timeframe to 150 days for the EMA’s Committee for Medicinal Products for Human Use (CHMP) to review the application.
In May 2020, Bristol-Myers announced that the FDA has extended the action date for its biologics license application (BLA) for lisocabtagene maraleucel (liso-cel) by three months. The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is Nov 16, 2020. Bristol-Myers had submitted additional information upon the agency’s request, which was deemed to constitute a major amendment to the application and will require additional time for FDA review.
A tentative approval of the candidate will boost Bristol-Myers’ portfolio and revenues.
However, competition is stiff in this space from the likes of Novartis’ (NVS - Free Report) Kymriah and Gilead Sciences, Inc.’s (GILD - Free Report) Yescarta.
Bristol-Myers’ shares have lost 3.8% in the year so far against the industry’s growth of 11.5%.
We note that the approval of new drugs has become more important for the company as its blockbuster drug, Opdivo, is facing stiff competition from Merck’s (MRK - Free Report) Keytruda.
Last month, the European Commission (EC) approved Reblozyl (luspatercept) for two indications — the treatment of adult patients with transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy, and those with transfusion-dependent anemia associated with beta thalassemia.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation
Bristol-Myers (BMY - Free Report) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for its experimental candidate, lisocabtagene maraleucel (liso-cel).
Liso-cel, an experimental CD19-directed chimeric antigen receptor (CAR) T cell therapy, is being evaluated for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B) after at least two prior therapies.
The validation of the application confirms that the submission is complete and the EMA will begin its centralized review process.
The application was based on results from TRANSCEND NHL 001, the largest study in third-line or greater R/R large B-cell lymphoma (LBCL), and additional data from the TRANSCEND WORLD study. The studies evaluated patients with R/R LBCL and included patients with a broad range of histologies and high-risk disease as well as those who received liso-cel in the outpatient setting.
We note that the EMA previously granted liso-cel access to the PRIME scheme for the treatment of R/R DLBCL and Accelerated Assessment status, which reduces the maximum timeframe to 150 days for the EMA’s Committee for Medicinal Products for Human Use (CHMP) to review the application.
In May 2020, Bristol-Myers announced that the FDA has extended the action date for its biologics license application (BLA) for lisocabtagene maraleucel (liso-cel) by three months. The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is Nov 16, 2020. Bristol-Myers had submitted additional information upon the agency’s request, which was deemed to constitute a major amendment to the application and will require additional time for FDA review.
A tentative approval of the candidate will boost Bristol-Myers’ portfolio and revenues.
However, competition is stiff in this space from the likes of Novartis’ (NVS - Free Report) Kymriah and Gilead Sciences, Inc.’s (GILD - Free Report) Yescarta.
Bristol-Myers’ shares have lost 3.8% in the year so far against the industry’s growth of 11.5%.
We note that the approval of new drugs has become more important for the company as its blockbuster drug, Opdivo, is facing stiff competition from Merck’s (MRK - Free Report) Keytruda.
Last month, the European Commission (EC) approved Reblozyl (luspatercept) for two indications — the treatment of adult patients with transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy, and those with transfusion-dependent anemia associated with beta thalassemia.
Bristol-Myers currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>